Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Aquestive Therapeutics Q3 2026 Results: Net Loss of $16.5M, Loss Widens

Aquestive Therapeutics reported a net loss of $47.4 million for the nine months ended September 30, 2026, compared to a loss of $54.9 million in the prior year period. Total revenues increased to $35.8 million from $31.5 million, while the company recognized a $11.7 million loss on the extinguishment of debt following the redemption of its 13.5% Notes.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue7.612.8
Profit before tax-16.5-15.4
Net income-16.5-15.4
EPS (diluted, $ a share)$-0.13$-0.14

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-41.0%
Operating margin-191.5%
Source

10-Q filed with the SEC, NASDAQ: AQST. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Aquestive Therapeutics, Inc.: key numbers

Share price
$3.76Close, Nov 16
Market cap
$473M
Shares outstanding
125.69MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Aquestive Therapeutics, Inc.

All →
6:37 AM ET 8-K
Investor Presentation

Aquestive Therapeutics Investor Presentation

Aquestive Therapeutics filed an investor presentation for the Jefferies Global Healthcare Conference on November 16, 2026. The presentation provides updates on the regulatory status of Anaphylm (epinephrine) sublingual film, including the March 16, 2027 PDUFA goal date, and the commercial launch strategy for the product if approved.

11:59 AM ET Form 4
Insider Buying

Aquestive Therapeutics Director Richard J. Daly Buys $95.1K of Stock

Richard J. Daly, Director, bought 26,825 shares of Aquestive Therapeutics, Inc. at $3.54 a share, worth $95.1K in total on Nov 10, 2026. Shares held after the trade: 28,025 (+2235.4%).

Value
$95.1K
Shares
26,825
Price
$3.54
Role
Director
Holding change
+2235.4%
Trade date
Nov 10, 2026
4:21 PM ET 8-K
Investor Presentation

Aquestive Therapeutics Investor Presentation

Aquestive Therapeutics filed a corporate investor presentation for November 2026 to be used in meetings with institutional investors and analysts. The presentation provides updates on the regulatory status of Anaphylm (sublingual epinephrine) following its NDA resubmission, which has a PDUFA goal date of March 16, 2027, and the development of its AdrenaVerse pipeline including AQST-108.

4:17 PM ET 8-K
Financial Results

Aquestive Therapeutics Financial Results

Aquestive Therapeutics reported Q3 2026 financial results and provided a regulatory update for its lead candidate Anaphylm, which has a PDUFA goal date of March 16, 2027. The company is preparing for a potential U.S. launch and plans to submit regulatory filings in Canada and the EU in late 2026 and early 2027.

Term
Q3 2026

“With a PDUFA goal date of March 16, 2027, we believe we have a clear path to making Anaphylm available to patients and caregivers, if approved. For decades, people at risk of anaphylaxis have had limited treatment options. We believe Anaphylm - designed to be easy to carry and use confidently whenever and wherever it may be needed - has the potential to address important unmet needs.”

Daniel Barber, President and Chief Executive Officer of Aquestive
2:17 PM ET Form 4
Insider Selling

Aquestive Therapeutics President and CEO Daniel Barber Sells $106K of Stock

Daniel Barber, President and CEO, sold 25,000 shares of Aquestive Therapeutics, Inc. at $4.22 a share, worth $106K in total on Oct 15, 2026. Shares held after the trade: 627,317 (-3.8%).

Value
$106K
Shares
25,000
Price
$4.22
Role
President and CEO
Holding change
-3.8%
Trade date
Oct 15, 2026
7:21 AM ET 8-K
Business Update

Aquestive Therapeutics Business Update

Aquestive Therapeutics announced that the FDA has accepted its NDA resubmission for Anaphylm (dibutepinephrine) sublingual film as complete and assigned a PDUFA goal date of March 16, 2027. The resubmission follows positive results from studies designed to address a prior Complete Response Letter, positioning Anaphylm to potentially become the first oral rescue medication for severe allergic reactions.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.